These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 9829163)

  • 1. Monoamine oxidase inhibitors. A perspective on their use in the elderly.
    Volz HP; Gleiter CH
    Drugs Aging; 1998 Nov; 13(5):341-55. PubMed ID: 9829163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current place of monoamine oxidase inhibitors in the treatment of depression.
    Shulman KI; Herrmann N; Walker SE
    CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase inhibitors. An update on drug interactions.
    Livingston MG; Livingston HM
    Drug Saf; 1996 Apr; 14(4):219-27. PubMed ID: 8713690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyramine and new monoamine oxidase inhibitor drugs.
    Simpson GM; de Leon J
    Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
    Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine.
    Hoffman GR; Olson MG; Schoffstall AM; Estévez RF; Van den Eynde V; Gillman PK; Stabio ME
    ACS Chem Neurosci; 2023 Dec; 14(23):4064-4075. PubMed ID: 37966854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F; Trivedi M; Thase ME
    Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression].
    Nolen WA
    Ned Tijdschr Geneeskd; 2003 Oct; 147(40):1940-3. PubMed ID: 14574774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.